

# VH-IVUS

## Matched and Mismatched with Clinical Manifestation


Seung-Jung Park, MD, PhD

Professor of Internal Medicine  
Asan Medical Center, *Seoul, Korea*




# Ruptured Plaques

What does it mean ?



Unfortunately, it is impossible to determine whether this lesion has the histologic and mechanical substrates for a rupture-prone plaque



Insights into pre-rupture morphology

# Why Virtual Histology ?


**To find out Vulnerable Plaque...**

# IVUS

- Conventional grey scale IVUS cannot detect vulnerable plaques
- Other IVUS based imaging modalities have the potential to detect vulnerable plaques,




# Virtual Histology -IVUS

In-vivo characterization of plaque composition via advanced spectral analysis






- Fibrous
- Fibro-fatty
- Necrotic
- Calcium

# Fibrotic Plaque




# Fibrofatty Plaque









# Necrotic Core







# Dense Calcium



# VH imaging is good correlation with pathologic findings

IVUS



Histology



# In vitro Validation of VH Tissue Characterization

## Eagle Eye VH Accuracy

VH IVUS vs histopathology from fresh post-mortem coronary arteries

	Sensitivity	Specificity	Predictive Accuracy
<b>Fibrous tissue (n=162)</b>	84.0%	98.8%	92.8%
<b>Fibrofatty (n=84)</b>	86.9%	95.1%	93.4%
<b>Necrotic core (n=69)</b>	97.1%	93.8%	94.4%
<b>Dense calcium (n=92)</b>	97.8%	99.7%	99.3%

G Vince, A Nair, ATL, Volcano Therapeutics, Cleveland








**Is VH imaging good correlation  
with clinical manifestation too ?**



# However, VH imaging is Matched and Mismatched with Clinical Manifestation


# Matched with IVUS and clinical presentation

## Patients with Stable Angina






# Matched with IVUS, OCT and VH in Patients with Stable Angina




# Matched with clinical manifestation

## Patient with UA







# Matched with IVUS, OCT and clinical presentation in Patients with Unstable Angina





# Mismatched with clinical manifestation

## Patient with Unstable Angina





# Mismatched with CAG, IVUS and clinical manifestation **Patient with STEMI**



**Thrombus**

# What is the Vulnerable Plaque in VH-IVUS ?



# VH Experience in Real World: *AMC Experience*




# VH-IVUS (1)

## Plaque Composition in Stable Angina vs. ACS

- 318 patients who underwent VH-IVUS in the de novo target/culprit lesions from May 2005 to July 2006.
- 318 patients composed of 195 SAP patients and 123 ACS patients (excluded ST elevation myocardial infarction).


# VH-IVUS Measurements

Planar VH-IVUS measurements were performed at 2 lesion segments (**minimum lumen cross-sectional area** and the **largest of necrotic core**) and volumetric analysis.




Minimal lumen CSA

Largest necrotic core burden



VH Analysis at  
(1) Minimal CSA  
(2) Volumetric Analysis



# Baseline Characteristics

	ACS (n=123)	SAP (n=195)	<i>p</i>
Age (yrs)	59±11	60±9	0.7
Men	92 (75%)	136 (70%)	0.4
Diabetes mellitus	21 (17%)	48 (25%)	0.147
Hypertension	47 (38%)	97 (50%)	0.050
Smoking	65 (53%)	38 (20%)	0.001
No. of disease vessel			0.018
One vessel	71 (58%)	139 (71%)	
Two vessel	35 (28%)	44 (23%)	
Three vessel	17 (14%)	12 (6%)	

# Baseline Characteristics

	ACS (n=123)	SAP (n=195)	<i>p</i>
Lipid profiles			
Total cholesterol (mg/dl)	185±42	168±35	<0.001
Triglyceride (mg/dl)	176±147	158±93	0.25
HDL-cholesterol (mg/dl)	39±11	44±13	0.004
LDL-cholesterol (mg/dl)	116±36	96±32	<0.001
hs-CRP level (mg/dl)	0.6±0.9	0.3±0.6	0.001



# Grey-scale IVUS

	ACS (n=123)	SAP (n=195)	p
<b>Minimum lumen area</b>			
EEM CSA (mm <sup>2</sup> )	17.1±4.5	15.0±4.5	0.001
Lumen CSA (mm <sup>2</sup> )	3.7±1.0	3.8±0.9	0.3
Plaque CSA (mm <sup>2</sup> )	13.1±4.4	10.9±4.4	0.001
Remodeling index	1.07±0.18	1.02±0.19	0.038
<b>Largest necrotic core</b>			
EEM CSA (mm <sup>2</sup> )	17.4±4.4	15.7±5.4	0.003
Lumen CSA (mm <sup>2</sup> )	4.8±1.7	5.0±2.1	0.3
Plaque CSA (mm <sup>2</sup> )	12.6±4.2	10.7±4.4	0.001
<b>Volumetric analysis</b>			
● EEM CSA (mm <sup>3</sup> )	167.7±43.8	149.2±40.5	0.001
Lumen CSA (mm <sup>3</sup> )	59.5±15.6	60.1±14.1	0.7
● Plaque CSA (mm <sup>3</sup> )	108.3±36.7	89.1±34.4	0.001

# VH-IVUS Measure at minimal lumen area


	ACS (n=123)	SAP (n=195)	p
<b>Absolute area (mm<sup>2</sup>)</b>			
Fibrotic	5.3±2.7	4.6±3.0	0.030
Fibrofatty	0.5±0.6	0.5±0.6	0.6
Dense calcium	0.8±0.7	0.6±0.6	0.001
Necrotic core	3.1±1.9	2.1±1.3	0.001
<b>Percentage (%)</b>			
Fibrotic	53±15	56±15	0.073
● Fibrofatty	5±5	7±6	0.020
Calcific	9±7	8±8	0.4
● Necrotic	33±14	29±14	0.015

# VH-IVUS Measure at largest necrotic core

	ACS (n=123)	SAP (n=195)	p
<b>Absolute area (mm<sup>2</sup>)</b>			
Fibrotic	5.0±4.3	4.0±2.8	0.015
Fibrofatty	0.4±0.4	0.4±0.5	0.6
Dense calcium	0.9±0.7	0.7±0.7	0.003
Necrotic core	3.4±2.0	2.3±1.6	0.001
<b>Percentage (%)</b>			
Fibrotic	50±15	53±15	0.105
Fibrofatty	4±4	5±5	4
Calcific	10±7	9±8	0.5
Necrotic	36±13	33±14	0.034


# VH-IVUS in volumetric analysis

	ACS (n=123)	SAP (n=195)	p
<b>Absolute area (mm<sup>3</sup>)</b>			
Fibrotic	41.9±22.4	32.3±20.8	0.001
Fibrofatty	4.7±4.5	4.5±4.7	0.7
Dense calcium	6.4±5.1	4.4±4.6	0.001
Necrotic core	20.3±12.6	14.3±9.5	0.001
<b>Percentage (%)</b>			
Fibrotic	56±13	57±13	0.3
● Fibrofatty	6±5	8±5	0.045
Calcific	9±7	9±8	0.5
● Necrotic	29±12	27±11	0.081



## High Risk TCFA

- a. Confluent NC > 20%
- b. No evidence of fibrotic cap
- c. Calcium > 5%
- d. Remodeling index > 1.05
- e. > 50% CSA luminal narrowing by IVUS





# VH-IVUS in Acute Coronary Syndrome

- Compared with SAP patients, plaque CSA was larger in ACS patients because of positive coronary remodeling
- Unstable lesions (plaque rupture plus VH-TCFA lesions) were more frequently observed in ACS patients than in SAP patients.
- Larger area of necrotic core and smaller area of fibrotic and fibrofatty plaque were observed in the culprit lesions of ACS patients than in the target lesions of SAP patients.
- More data should be gathered to evaluate the efficacy of VH-IVUS examination.


# VH-IVUS (2)

## Impact of Plaque Composition on Post-myocardial Necrosis



# VH Study in AMC

## Plaque Composition & Myocardial Necrosis

- 305 patients with de novo lesions underwent pre-intervention VH-IVUS study at AMC. In 80 of these 305 patients, stents were implanted into *a single de novo lesion*.
- Patients with acute or recent MI were excluded.
- To avoid confusion in determining which lesion was responsible for CK-MB elevation, patients with multi-vessel or multi-lesion PCI were also excluded from this study.



Pre-intervention



Post-intervention

Peak CK-MB release after stent implantation was 21.2 ng/ml.

# Baseline Characteristics

Age (yrs)	60±10
Men	44 (55%)
Diabetes mellitus	14 (18%)
Hypertension	42 (53%)
Smoking	28 (35%)
No. of disease vessel	
One vessel	73 (91%)
Two vessel	7 (9%)
Three vessel	0
Clinical presentation	
Stable angina	65 (81%)
Unstable angina	15 (19%)



# IVUS analysis

<i>Conventional IVUS</i>	No (n=76)	Yes (n=4)	P
EEM area (mm <sup>2</sup> )	13.5 <sub>±</sub> 3.2	16.2 <sub>±</sub> 4.2	0.106
Lumen area (mm <sup>2</sup> )	3.9 <sub>±</sub> 0.5	3.7 <sub>±</sub> 0.3	0.5
Plaque area (mm <sup>2</sup> )	9.4 <sub>±</sub> 3.2	12.5 <sub>±</sub> 4.2	0.072
EEM volume (mm <sup>3</sup> )	136.3 <sub>±</sub> 29.5	161.3 <sub>±</sub> 46.1	0.112
Lumen volume (mm <sup>3</sup> )	58.8 <sub>±</sub> 11.9	60.7 <sub>±</sub> 19.9	0.8
Plaque volume (mm <sup>3</sup> )	77.5 <sub>±</sub> 23.5	100.6 <sub>±</sub> 30.0	0.062

Myocardial necrosis : CK-MB elevation > 3 times of normal

# VH-IVUS analysis

## At minimal lumen site

Absolute amounts	No (n=76)	Yes (n=4)	P
Fibrotic plaque area (mm <sup>2</sup> )	3.9±2.2	5.3±4.2	0.24
Fibrofatty plaque area (mm <sup>2</sup> )	0.5±0.5	0.1±7	0.21
Dense calcium area (mm <sup>2</sup> )	0.5±0.7	0.6±0.6	0.8
● Necrotic core area (mm <sup>2</sup> )	1.7±0.9	3.3±0.6	0.001
Fibrotic plaque volume (mm <sup>3</sup> )	26.7±14.8	39.4±23.6	0.11
● Fibrofatty plaque volume (mm <sup>3</sup> )	3.4±2.9	1.3±0.9	0.005
Dense calcium volume (mm <sup>3</sup> )	3.8±4.0	5.6±2.8	0.4
● Necrotic core volume (mm <sup>3</sup> )	11.7±6.7	19.7±3.9	0.021

# VH-IVUS analysis

## At minimal lumen site

Relative amounts (%)	No (n=76)	Yes (n=4)	P
Fibrotic plaque area	57±15	52±20	0.5
● Fibrofatty plaque area	6±6	1±1	0.001
Dense calcium area	9±9	9±8	1.0
● Necrotic core area	28±13	39±14	0.097
Fibrotic plaque volume	58±13	56±15	0.8
● Fibrofatty plaque volume	7±5	2±1	0.001
Dense calcium volume	9±8	10±8	0.7
Necrotic core volume	26±11	32±8	0.3

# Correlates of post-PCI CK-MB level

Grey scale IVUS

	r	95% CI	p
EEM area (mm <sup>2</sup> )	0.232	0.012 – 0.444	0.039
Lumen area (mm <sup>2</sup> )	0.144	-2.248 - 0.483	0.202
P&M area (mm <sup>2</sup> )	0.274	0.056 – 0.476	0.014
Plaque burden (%)	0.249	0.972 – 14.859	0.026
Remodeling index	0.262	1.472 – 11.764	0.013
EEM volume (mm <sup>3</sup> )	0.203	-0.002 – 0.044	0.071
Lumen volume (mm <sup>3</sup> )	0.036	-0.050 – 0.069	0.8
P&M volume (mm <sup>3</sup> )	0.239	0.003 – 0.061	0.033


# Correlates of post-PCI CK-MB level

VH-IVUS

	r	95% CI	p
Fibrotic plaque area (mm <sup>2</sup> )	0.182	-0.056 – 0.567	0.11
Fibrofatty plaque area (mm <sup>2</sup> )	0.079	-1.921 – 0.926	0.5
Dense calcium area (mm <sup>2</sup> )	0.064	-0.809 – 1.446	0.6
Necrotic core area (mm <sup>2</sup> )	0.371	0.546 – 1.957	0.001
Fibrotic plaque volume (mm <sup>3</sup> )	0.195	-0.005 – 0.087	0.087
Fibrofatty plaque volume (mm <sup>3</sup> )	0.099	-0.356 – 0.138	0.4
Dense calcium volume (mm <sup>3</sup> )	0.139	-0.068 – 0.290	0.220
Necrotic core volume (mm <sup>3</sup> )	0.278	0.029 – 0.232	0.013



**Level of CK-MB (ng/mL)**



**Necrotic core area (mm<sup>2</sup>)**

# Predictors of post-PCI CK-MB level

VH-IVUS

Multivariable linear regression analysis - including all variables with  $p < 0.2$  in univariable analysis - indicated that the *absolute necrotic core area* was the only independent predictor of CK-MB enzyme level after PCI ( $r=0.371$ , 95% CI= 0.546 to 1.957 and  $p=0.001$ ).

# VH - IVUS : Post PCI-myocardial necrosis

- Post-PCI CK-MB enzyme level correlated with a larger pre-PCI necrotic core area at the minimal lumen site as assessed by VH-IVUS analysis.
- More aggressive medical treatment and less aggressive procedures may be warranted to prevent higher CK-MB elevations in these lesion subsets.

# Vulnerable Plaque vs Vulnerable Patients?




# 67/M, Unstable Angina

- DM for 15 years
- Hypertension under medications
- Cholesterol 238 mg/dl, LDL 162mg/dl
- Heavy smoker 1 pack/ 20 years
  
- No EKG changes
- No cardiac enzyme changes



# 67/M, Unstable Angina

## 2 vessel disease









# Distal LCX



# Proximal LCX





# LMCA









# LAD



# RCA



# Multiple Vulnerable Plaque < Vulnerable Patients

We have no data about prospective identification of vulnerable plaques before they rupture and/or thrombus formation



# PROSPECT

## Providing Regional Observations to Study Predictors of Events in the Coronary Tree

Natural history study in pts with ACS

700 pts with ACS and 1 or 2 vessel CAD undergoing PCI will have QCA of entire coronary tree, culprit artery imaging (post PCI), and both non-culprit arteries also imaged using IVUS, Virtual histology, Palpography,  $\pm$  Thermography (EU only)

### Meds Rx

Aspirin  
Plavix 1yr  
Statin

F/U: 1 mo, 6 mo, 1 yr  
2 yr,  $\pm$ 3-5 yr  
(event driven)

Repeat imaging  
in pts with events